Table 1:

Model parameters

Parameter	Value (range)	Source
Age, yr, mean	35.9	Patient data from MRHC
Age at symptom onset, yr	55 (36–84)	Whitty et al.21
Probability
Of patient being female	0.487	Patient data from MRHC
Of patient being infected	0.232 (0.181–0.293)	Patient data from MRHC
Of test result being positive, given presence of infection	0.99	NRCP22
Of test result being negative, given absence of infection	0.90	NRCP22
Of patient consenting to screening test	0.98	Patient data from MRHC
Of patient accepting treatment, given positive test result	0.88 (0.82–0.94)	Patient data from MRHC
Of patient accepting empiric treatment	0.88 (0.82–0.94)	Patient data from MRHC
Of patient being cured by treatment	0.88 (0.799–0.929)	Whitty et al.,21 Danso-Appiah et al.23
Of hepatosplenic (v. urinary) involvement, given infection	0.45	Patient data from MRHC
Of urinary obstruction, given infection	0.287 (0–0.431)	Smith et al.24
Of hydronephrosis, given infection	0.228 (0–0.342)	Smith et al.24
Of pyelonephritis, given obstruction	0.197 (0–0.295)	Smith et al.24
Of bacteremia, given pyelonephritis	0.143 (0–0.341)	Stamm25
Of genital disease, given infection in female	0.333 (0–0.500)	Gelfand et al.26
Of bladder cancer, given infection	0.027 (0–0.041)	Smith et al.24
Of intestinal disease, given infection	0.133 (0–0.200)	Prata27
Of portal fibrosis, given infection	0.139 (0–0.209)	Cheever and Andrade28
Of ascites, given fibrosis	0.070 (0.010–0.100)	Andrade29
Of hematemesis, given fibrosis	0.027 (0–0.040)	Saad et al.30
Of death, given hematemesis	0.153 (0–0.230)	Reboucas31
Of pulmonary hypertension, given fibrosis	0.186 (0–0.230)	Prata27
Of cor pulmonale, given fibrosis	0.050 (0–0.075)	Prata27
Of glomerulonephritis, given fibrosis	0.067 (0–0.100)	Prata27
Of central nervous system involvement, given infection	0.001 (0–0.002)	Cheever and Andrade28
Standardized mortality ratio for refugees in Canada	0.53	DesMeules et al.32
Mean life expectancy at age 36 yr for Canadians, yr	46.7	Statistics Canada33
Mean life expectancy at age 36 yr for refugees resettled in Canada, yr	52.9	DesMeules et al.,32 Statistics Canada33
Mean survival for patients with glomerulonephritis, yr	17.3	Heaf et al.34
Mean survival for patients with pulmonary hypertension, yr	9.4	Oswald-Mammosser et al.35
Mean survival for patients with bladder cancer, yr	5.3	Ehdaie et al.36
Mean survival for patients with cor pulmonale, yr	7.0	Opitz et al.37
Mean survival for patients with portal hypertension, yr	27.8	Siramolpiwat et al.38
Duration of treatment for infertility, yr	4.1	Collins et al.39
Utility discount rate, %	1.5	CADTH40
Cost discount rate, %	1.5	CADTH40
Mean dose of praziquantel, mg	1000	Personal communications^*
Cost of praziquantel, $	47.93 (44.66–51.19)	Personal communications^*
Cost of serology, $	74.09 (61.21–86.97)	Personal communications^†

Note: CADTH = Canadian Agency for Drugs and Technology in Health, MRHC = Mosaic Refugee Health Clinic, NRCP = National Reference Centre for Parasitology.
↵* Personal communications: David Brewerton, pharmacist, Luke’s Drug Mart, Calgary; Joel Varsava, pharmacist, Pharmacity, Ottawa (for additional detail, see Appendix 1, available at www.cmajopen.ca/content/9/1/E125/suppl/DC1).
↵† Personal communications: Jayne Jones, Liverpool School of Tropical Medicine, and Mary Kamb, department of public inquiries, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention (for additional detail, see Appendix 1).